Product Description
Mechanisms of Action: ER Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: European Medicines Agency | India
Approved Indications: None
Known Adverse Events: None
Company: Repros
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Infertility, Male|Hypogonadism|Overweight
Phase 2: Hypogonadism|Type 2 Diabetes|Obesity
Phase 1: Healthy Volunteers|Hypogonadism|Kidney Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ZA-205 | P2 |
Completed |
Obesity|Hypogonadism |
2017-05-02 |
22% |
| PROTOCOL #01-14-40-08 | P3 |
Withdrawn |
Infertility, Male |
2016-08-02 |
|
| ZA-303 | P3 |
Completed |
Hypogonadism |
2014-09-01 |
|
| ZA-104 | P1 |
Completed |
Kidney Diseases|Hypogonadism |
2014-08-01 |